Alzheimer disease (AD) is the most common form of senile dementia, with no effective treatment available. In a study appearing online on August 11 in advance of print publication of the September 1 issue of the Journal of Clinical Investigation, Howard Weiner and colleagues from Harvard describe a novel immunologic approach for the treatment of AD.

Previous studies utilizing immunization against Abeta, a key pathogenic player in AD, to generate antibodies against Abeta were discontinued because of unacceptable side effects in AD patients.

Here, the researchers use a specific nasal vaccination to decrease AD burden in mice. The vaccine consists of an FDA-approved drug currently used to treat multiple sclerosis (called glatiramer acetate) plus a recently developed nasal adjuvant that has been shown to be safe in humans and activates microglia, cells which then clear beta-amyloid in the brain without evidence of toxic effects.

The findings have both basic and clinically relevant implications. The discovery of a non-antibody mediated method to clear Abeta could be used as a treatment for patients who already are showing signs of AD. Moreover, the compounds used have already been safely tested in humans.

'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
11-Aug-2005

Page: 1
Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Effective new biodiversity data access portal
3. PET/CT use expands: Effectively diagnosing graft infections
4. Effectiveness of certain antidepressants may be influenced by gene variations of individuals
5. UCF, NIH study: Effective, safe anthrax vaccine can be grown in tobacco plants
6. Effective cancer treatments follow the clock
7. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
8. Link identified between Alzheimers disease and glaucoma
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Journal of Alzheimers Disease achieves significant impact factor
11. Alzheimers prevention role discovered for prions